U.S. Health Spending Topped $5 Trillion for the First Time. That’s Trillion With a ‘T’

And SureScripts and GoodRx are teaming up to give patients real-time info on what their meds will cost

With MFN Deals in the Rear-View Mirror, Pharma CEOs at JPM Say They Can ‘Focus More on the Fundamentals’

And a new resource from J&J underscores the need to protect the U.S. patent system

Why One Small Company -- About to Take on an Industry Giant -- Won’t Compete on Price

And AbbVie joins the long list of companies that have struck deals with the White House

Six Policy Questions that J.P. Morgan Presentations May Help Answer

And early evidence of how the $2,000 out-of-pocket cap is helping patients ... and where it’s falling short

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

And list prices are falling on medicines that generated a total of $50 billion in sales last year

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

And a Health Affairs paper explains how 340B hospitals in 27 states can siphon savings that would otherwise accrue to state Medicaid programs

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

And how one pharmaceutical company expects to see revenue spike ... by slashing the list price of its medicine

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

The Jan. 1 pricing decisions for the 10 best-selling medicines might surprise you

We're Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

And a critical 2026 trend -- dropping list prices on blockbuster drugs -- has begun with a 40%+ cut to Imbruvica’s price

Christmas Comes Early for the Wonks, With CMS Demonstrations and MFN Announcements

And the results of the “Nobody Knows” Prediction Contest

The Number of Companies Set to Make MFN Announcements Today Is Up to At Least Six

Plus, a rosy AARP survey suggests that Medicare “negotiations” will lower out-of-pocket costs. The truth is likely to be more complicated.

Novartis, Roche, AbbVie Reportedly on Deck for White House MFN Announcements Tomorrow

And introducing the first annual ‘Nobody Knows’ Prediction Contest

Please Celebrate Festivus With Cost Curve by Airing Your Grievances

And Pfizer’s take on the pharm-to-table opportunity in obesity: ‘Multiples of what we were expecting’

Arnold Ventures' 2024 Grant Awards Are Now Public. Here’s What Those Dollars Say About the Group's Goals

And Pfizer offers few new details on how the MFN deal will impact the company’s bottom line next year

Big Companies Are Far Less Likely to Disclose Drug Prices Than Smaller Ones, New Study Shows

My research with Tufts CEVR on drug-price announcements, published today in AJMC, assessed 150 meds over three years

Sales at 340B Prices Continue to Skyrocket -- Jumping to More than $81 Billion -- Even as Questions Remain About Where the Money Goes

And a Tufts CEVR analysis suggests that cost-effectiveness is not playing a meaningful role in government price-setting efforts

A New Tracker for Watching Meds That Might See Prices Slashed

And an evolving list of all of the pricing and policy fun to be had between now and Christmas

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

And the 340B rebate model debate is coming to Cost Curve’s home turf: Portland

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

And a STAT analysis suggests that major health insurers are seeing med spending skyrocket, but a closer look at the data raises questions

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

And lawmaker talk of PBM reform has returned. Will action follow?

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

The U.K. Will Make Efforts to Boost Drug Prices in Return for the Elimination of U.S. Tariffs

And the pharm-to-table pricing of obesity medicines gets even more dizzying as Lilly cuts the price of Zepbound vials

The Search for Clarity on the Differences Between IRA and MFN Prices for Ozempic and Wegovy

And an FDA official calls out ‘unique financial incentives for vaccine makers’